Celladon (CLDN) is a clinical-stage biotechnology company that postponed their IPO at when it was being marketed at much higher prices. They've jumped back into the market with a much-reduced proposed price of $8/share and some interest from insiders in buying shares on the IPO. The deal is now $40M in value and the pro-forma market capitalization would be $138M.
The lead drug candidate at Celladon (MYDICAR) targets heart failure and is currently in Phase 2 trials. Heart failure is one of the big ones in terms of disease market opportunity which is a plus . . .